Study to Evaluate Safety, Pharmacokinetic and Pharmacodynamic Dose Escalation and Expansion Study of PXS-5505 in Patients With Primary, Post-polycythemia Vera or Post-essential Thrombocythemia Myelofibrosis

Myelofibrosis Clinical Trial

Official title:

A Phase 1/2a Study to Evaluate Safety, Pharmacokinetic and Pharmacodynamic Dose Escalation and Expansion Study of PXS-5505 in Patients With Primary, Postpolycythemia Vera or Post-essential Thrombocythemia Myelofibrosis

Clinical Trial Details — Status: Recruiting

Administrative data

• NCT number: NCT04676529
• Other study ID #: PXS5505-MF-101
• Status: Recruiting
• Phase: Phase 1/Phase 2
• Start date: February 18, 2021
• Est. completion date: August 2025

Study information

• Verified date: November 2023
• Source: Syntara
• Contact: Jana Baskar, MBBS MMedSc MBA
• Phone: +61 487 651 726
• Email: jana.baskar[@]syntaratx.com.au
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

This study will be an open-label phase 1/2a study to evaluate the safety and tolerability of PXS-5505 in patients with primary, postpolycythemia vera (PV) or post-essential thrombocythemia (ET) myelofibrosis.

Description:

The study consists of three phases: a dose escalation phase, a cohort expansion phase, and an add-on phase. The dose escalation phase will follow a 3+3 design with a starting dose of 100 mg twice daily, and a treatment duration of 4 weeks. Patients will be able to participate in more than one dose level. During the cohort expansion phase, up to 24 patients will be treated at the dose determined appropriate based on safety, pharmacokinetic and pharmacodynamic results from the dose escalation phase, for a period of up to 6 months. Patients from the dose escalation phase will be able to participate in the cohort expansion phase. In the add-on phase PXS-5505 will be given to patients, already receiving a stable dose of ruxolitinib, for a period of 12 months. Up to 15 patients will enrol in the add-on phase in order to obtain 12 patients with at least 1 month's exposure to PXS-5505 on top of ruxolitinib. Note: The decision to include an add-on phase, where PXS-5505 is to be given on top of a stable ruxolitinib dose, was taken following a review of the data (safety, PK and PD) from the cohort expansion phase. There will be no washout period between dose escalation and dose expansion cohorts.

Recruitment information / eligibility

• Status: Recruiting
• Enrollment: 39
• Est. completion date: August 2025
• Est. primary completion date: August 2025
• Accepts healthy volunteers: No
• Gender: All
• Age group: 18 Years and older

Eligibility

Inclusion Criteria:

• Have a pathologically confirmed established diagnosis of primary myelofibrosis or post-essential thrombocythemia/polycythemia vera myelofibrosis as per the World Health Organization 2016 diagnostic criteria (must include at least Grade 2 marrow fibrosis)
• Patients who are not eligible for stem cell transplantation
• a) Dose escalation / Cohort expansion phase only: Patients not currently on ruxolitinib or fedratinib (where available) treatment due to ineligibility, or previously treated patients who have been discontinued for at least 2 weeks prior to

first dose of study drug due to any of the following criteria:

• Ineligible: Platelets <50 x 10^9/L
• Intolerant: Development of red blood cell transfusion dependence of at least two units/month for 2 months OR =Grade 3 adverse events of thrombocytopenia, anemia, hematoma, and/or hemorrhage while on treatment with ruxolitinib or fedratinib for at least 28 days
• Refractory: < 10% spleen volume reduction by MRI or CT, or < 30% decrease from baseline in spleen volume by palpation after at least 3 months treatment with ruxolitinib or fedratinib
• Relapsed: Regrowth to < 10% spleen volume reduction by MRI or CT, or < 30% decrease from baseline in spleen volume by palpation, following an initial response to ruxolitinib or fedratinib and after at least 3 months treatment
• b) Add-on phase only: Are being treated with ruxolitinib for at least 12 weeks prior to first administration of study treatment. The patient must be on a stable dose (no dose adjustments) of ruxolitinib for = 8 weeks prior to study treatment and have not achieved complete remission (CR) by International Working Group (IWG) criteria.
• Have intermediate -2, or high-risk disease according to the International Working Group prognostic scoring system (DIPSS);
• a) Dose escalation / Cohort expansion phase only: Have symptomatic disease according to the MFSAF v4.0; Symptomatic disease is defined as a score of at least one in at least two items of the MFSAF v4.0; b) Add-on phase only: have a score of = 10 on the MFSAF v4.0;
• Have symptomatic disease according to the MFSAF v4.0;
• Life expectancy of six months or greater;
• Must have adequate organ function as demonstrated by the following (within last 2

weeks):

• Alanine aminotransferase and/or aspartate aminotransferase = 2.5x upper limit of normal (ULN), or = 4 x ULN (if upon judgment of the treating physician, it is believed to be due to extramedullary hematopoiesis [EMH] related to MF);
• Direct bilirubin = 1.5 x ULN; or = 2 x ULN (if upon judgment of the treating physician, it is believed to be due to EMH related to MF);
• Estimated glomerular filtration rate (eGFR) > 50 mL/min
• Eastern Cooperative Oncology Group performance status = 2;
• Men must agree to using one medically approved contraceptive measure and have their partners agree to an additional barrier method of contraception for the duration of the study and for 90 days after the last administration of study drug; women of childbearing potential must use effective contraception
• Cohort Expansion and Add-on Phase only: A bone marrow biopsy must have been performed within 3 months prior to Day 1 treatment to establish the baseline fibrosis score or within 6 months of the re-initiation of treatment with PXS-5505 if subject participated in dose escalation phase of the trial

Exclusion Criteria:

• Greater than (>) 10% blasts in peripheral blood (determined within last two weeks);
• Prior splenectomy, or planning to undergo splenectomy, or splenic irradiation within 3 months prior to the first dose of study treatment
• Any serious medical condition or psychiatric illness that would prevent (as judged by the treating physician) the subject from signing the informed consent form or any condition, including the presence of laboratory abnormalities, which places the subject at unacceptable risk if he/she were to participate in the study or confounds the ability to interpret data from the study
• Known history of human immunodeficiency virus, active hepatitis C, or active hepatitis B
• History or presence of any form of cancer within the three years prior to enrolment, with the exception of excised basal cell or squamous cell carcinoma of the skin, or cervical carcinoma in situ or breast carcinoma in situ that has been excised or resected completely and is without evidence of local recurrence or metastasis
• Participation in an investigational drug or device trial within two weeks prior to study Day 1 or within five times the half-life of the investigational agent in the other clinical study, if known
• Use of any cytotoxic chemotherapeutic agents, including hydroxyurea, corticosteroids (prednisone = 10 mg/day or corticosteroid equivalent is allowed), or immune modulators (e.g., thalidomide) within two weeks and interferon use within four weeks prior to study Day 1
• Symptomatic congestive heart failure (New York Heart Association Classification Class II), unstable angina, or unstable cardiac arrhythmia requiring medication
• Pregnancy
• History of surgery within two weeks prior to enrolment or anticipated surgery during the study period or two weeks post-study
• History of aneurysm
• Any other condition that might reduce the chance of obtaining data required by the protocol or that might compromise the ability to give truly informed consent.

Related Conditions & MeSH terms

• Myelofibrosis
• Polycythemia
• Polycythemia Vera
• Primary Myelofibrosis
• Thrombocythemia, Essential
• Thrombocytosis

Intervention

Drug:
• PXS-5505
PXS-5505 is a hard capsule (size 0) with the additional excipients mannitol and magnesium stearate.

Locations

Country	Name	City	State
Australia	Ashford Cancer Centre Research	Adelaide	South Australia
Australia	St Vincent's Hospital Melbourne	Fitzroy	Victoria
Australia	Liverpool Hospital	Liverpool	New South Wales
Australia	One Clinical Research	Perth	Western Australia
Australia	The Perth Blood Institute	West Perth	Western Australia
Korea, Republic of	Inje University Busan Paik Hospital - Internal Medicine	Busan	Busan Gwang'yeogsi [Pusan-Kwan
Korea, Republic of	Keimyung University Dongsan Hospital	Daegu	Daegu Gwang'yeogsi [Taegu-Kwangyokshi]
Korea, Republic of	National Cancer Center (Seoul Metro; northern)	Gyeonggi-do
Korea, Republic of	Seoul National University Hospital - Bundang	Gyeonggi-do
Korea, Republic of	Gachon University Gil Hospital	Incheon	Incheon Gwang'yeogsi [Inch'n-K
Korea, Republic of	Asan Medical Centre	Seoul
Korea, Republic of	Samsung Medical Center	Seoul
Korea, Republic of	Seoul National University Hospital	Seoul
Korea, Republic of	Severance Hospital, Yonsei University Health System- Haemat	Seoul
Korea, Republic of	The Catholic University of Korea, Seoul St. Mary's Hospital	Seoul
Taiwan	Chang Gung Medical Foundation - ChiaYi Chang Gung Memorial Hospital - Hematology and Oncology	Chiayi City	Chiayi
Taiwan	Kaohsiung Medical University Chung-Ho Memorial Hospital	Kaohsiung
Taiwan	China Medical University Hospital - Internal Medicine - Taichung	Taichung
Taiwan	National Cheng Kung University Hospital	Tainan
Taiwan	National Taiwan University Hospital - Hematology And Oncology	Taipei
United States	Comprehensive Cancer Center (UAB CCC)	Birmingham	Alabama
United States	The University of Texas MD Anderson Cancer Center	Houston	Texas
United States	Novant Health Cancer Institute	Winston-Salem	North Carolina

Sponsors (1)

Lead Sponsor	Collaborator
Syntara

Countries where clinical trial is conducted

United States,  Australia,  Korea, Republic of,  Taiwan, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Number of subjects with serious and non-serious adverse events	Safety and tolerability of PXS-5505 in patients with myelofibrosis will be assessed	Day 0 to follow-up visit (28 days -1 to +7days post-Tx discontinuation [dose escalation phase]; Day 0 to 28 days ± 3 days post-Tx discontinuation [cohort expansion phase]); Day 0 to follow-up visit (28 days ± 3 days post-Tx discontinuation [add-on phase]
Secondary	Maximum plasma concentration (C1hr=Cmax)	Pharmacokinetic parameters of PXS-5505 in patients with myelofibrosis will be assessed.	Day 0, week 1 and week 4 (dose escalation), and Day 0, week 4, 12 and 24 (cohort expansion and add-on phase), and week 52 during add-on phase only
Secondary	Minimum plasma concentration (Cmin)	Pharmacokinetic parameters of PXS-5505 in patients with myelofibrosis will be assessed.	Day 0, week 1 and week 4 (dose escalation), and Day 0, week 4, 12 and 24 (cohort expansion and add-on phase), and week 52 during add-on phase only
Secondary	Lysyl oxidase and lysyl oxidase-like 2 inhibition in plasma	Pharmacodynamic parameters of PXS-5505 in patients with myelofibrosis will be assessed.	Day 0, week 1 and week 4 dose escalation, and at week 0, 4, 12, 24 (cohort expansion and add-on phase), and week 52 during add-on phase only
Secondary	Change in bone marrow (BM) fibrosis	Change in bone marrow fibrosis will be assessed according to European Consensus on grading of bone marrow fibrosis	Day 0, Week 12 and Week 24 (cohort expansion and add-on phase), and week 52 during add-on phase only
Secondary	Response rate	Response rates as defined by International Working Group (IWG)-Myeloproliferative Neoplasms Research and Treatment criteria in patients with myelofibrosis administered PXS-5505 will be determined.	At week 12 and week 24 (cohort expansion and add-on phase), weeks 38 and 52 during add-on phase only
Secondary	Changes in spleen volume	Changes in spleen volume, as measured by computed tomography (CT) or magnetic resonance imaging (MRI) scan, in patients with myelofibrosis administered PXS-5505 will be determined.	Day 0, week 12, and week 24 (cohort expansion and add-on phase), weeks 38 and 52 during add-on phase only
Secondary	Changes in myelofibrosis related symptoms	Changes in myelofibrosis related symptoms based on Myelofibrosis-Symptom Assessment Form (MFSAF) v4.0 scores, in patients with myelofibrosis administered PXS-5505 will be determined. A higher score indicates worse symptoms.	Screening, week 12, and week 24 (cohort expansion and add-on phase), weeks 38 and 52 during add-on phase only
Secondary	Percentage of patients with hematological changes	Hematological changes will be determined	Day 0, week 12, and 24 (cohort expansion and add-on phase), weeks 38 and 52 during add-on phase only